Compounded Tirzepatide vs. Mounjaro/Zepbound: What Clinics Need to Know in 2026
Clinics prescribing tirzepatide face the same compounded vs. brand-name question as semaglutide — but with different regulatory dynamics. This guide covers the 2026 landscape for tirzepatide supply.
Compounded Tirzepatide vs. Mounjaro/Zepbound: What Clinics Need to Know in 2026
Tirzepatide — the dual GLP-1/GIP agonist sold as Mounjaro (for type 2 diabetes) and Zepbound (for obesity) — has become one of the most prescribed medications in the US. And like semaglutide, it has been at the center of the compounded vs. brand-name debate.
Here is the 2026 landscape for clinics.
The Shortage List History
Tirzepatide was added to the FDA drug shortage list in 2022 as demand outpaced Eli Lilly's manufacturing capacity. During the shortage period, 503A and 503B compounders had broader latitude to produce tirzepatide preparations.
The FDA removed tirzepatide from the shortage list in late 2024, which significantly changed the compliance landscape for compounded tirzepatide.
What the Shortage List Removal Means
When a drug is removed from the FDA shortage list, the specific "shortage" basis for 503A compounding of that drug largely disappears. This means:
- Compounding a copy of commercially available tirzepatide is generally not permitted under 503A unless there is a documented patient-specific reason the commercial product cannot be used
- The patient-specific reasons that may still support compounding include: allergy to inactive ingredients, need for a strength not commercially available, or need for an alternative delivery form
- Each of these requires documentation in the patient's medical record
When Compounded Tirzepatide May Still Be Appropriate
Despite the shortage list removal, there are still legitimate clinical scenarios:
- Documented allergy to an inactive ingredient in Mounjaro or Zepbound
- Strength requirements not available commercially (e.g., very low starting doses)
- Alternative delivery forms not commercially available
- Combination formulations with other compounds
Your prescribing decisions should be made in consultation with your legal counsel and compliance team.
The Commercial Product Landscape
Mounjaro and Zepbound are now more widely available than during the shortage period. Prior authorization requirements remain a barrier for some patients, but access has improved significantly.
For patients who can access the commercial product, the brand-name option is generally the cleaner compliance path.
MedClinic Partners' Approach
We work only with 503A and 503B compounding pharmacies that maintain rigorous compliance with current FDA guidance. Our legal team monitors FDA 503A/503B guidance in real time and provides proactive compliance support to our provider network.
Apply for portal access — NPI verified in 60 seconds.
Related reading: Compounded Semaglutide vs Brand Name · 503A vs 503B Explained · Compliance Standards
Explore Topics
Written by
MedClinic Partners Editorial Team
B2B Medical Supply & Compounding Experts
The MedClinic Partners editorial team is composed of licensed medical operators, compounding compliance specialists, and professionals with mass-tort pharmaceutical backgrounds and direct experience running GLP-1 and peptide programs across all 50 states. Every article is reviewed for clinical accuracy, regulatory compliance, and practical applicability before publication.
Editorial standards: All content on medclinicpartners.com is reviewed by licensed medical operators and compounding compliance specialists before publication. Articles are updated when regulatory guidance changes. This content is for licensed healthcare providers only and does not constitute medical advice.
